Jazz Pharmaceuticals Plc Share Price Today
(NASDAQ: JAZZ)

Name: Jazz Pharmaceuticals Plc Share Price Today (NASDAQ: JAZZ) - Jazz Pharmaceuticals Plc Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Jazz Pharmaceuticals Plc share price is $121.63 & ₹10,593.36 as on 5 Feb 2025, 2.30 'hrs' IST

$121.63

▲

-0.34

(-0.28%)

Market is closed - opens 8 PM, 05 Feb 2025

View live Jazz Pharmaceuticals Plc share price in Dollar and Rupees. Guide to invest in Jazz Pharmaceuticals Plc stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Jazz Pharmaceuticals Plc, along with analyst recommendations, forecasts, and comprehensive financials.

Jazz Pharmaceuticals Plc share price movements

Today's Low: $120.96
Today's High: $122.38
$121.63
0.55%
Downside
Day's Volatility :1.16%
Upside
0.61%
52 Weeks Low: $99.06
52 Weeks High: $134.17
$121.63
18.56%
Downside
52 Weeks Volatility :26.17%
Upside
9.35%

Jazz Pharmaceuticals Plc (JAZZ) Returns

Period	Jazz Pharmaceuticals Plc	Sector (Health Care)	Index (Russel 2000)
3 Months	9.34%	0.5%	0.0%
6 Months	8.66%	-2.3%	0.0%
1 Year	-2.2%	3.8%	0.0%
3 Years	-13.58%	11.4%	-11.7%

Jazz Pharmaceuticals Plc (JAZZ) Key Statistics

in dollars & INR

Previous Close	$121.97
Open	$121.07
Today's High	$122.38
Today's Low	$120.955
Market Capitalization	$7.5B
Today's Volume	$423.4K
52 Week High	$134.17
52 Week Low	$99.06
Revenue TTM	$4.0B
EBITDA	$1.5B
Earnings Per Share (EPS)	$7.06
PE Ratio	17.62
Profit Margin	11.6%
Quarterly Earnings Growth YOY	0.6%
Return On Equity TTM	12.09%

How to invest in Jazz Pharmaceuticals Plc Stock (JAZZ) from India?

It is very easy for Indian residents to invest directly in Jazz Pharmaceuticals Plc from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Jazz Pharmaceuticals Plc stock in both Indian Rupees (INR) and US Dollars (USD). Search for Jazz Pharmaceuticals Plc or JAZZ on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Jazz Pharmaceuticals Plc or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Jazz Pharmaceuticals Plc shares which would translate to 0.007 fractional shares of Jazz Pharmaceuticals Plc as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Jazz Pharmaceuticals Plc, in just a few clicks!

Returns in Jazz Pharmaceuticals Plc (JAZZ) for Indian investors in Rupees

The Jazz Pharmaceuticals Plc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Jazz Pharmaceuticals Plc investment value today

Current value as on today

₹1,02,395

Returns

₹2,395

(+2.39%)

Returns from Jazz Pharmaceuticals Plc Stock

₹2,470 (-2.47%)

Dollar Returns

₹4,865 (+4.86%)

Indian investors sentiment towards Jazz Pharmaceuticals Plc (JAZZ)

-46%

Period: Jan 5, 2025 to Feb 4, 2025. Change in 30 Days versus previous period

Search interest for Jazz Pharmaceuticals Plc Stock from India on INDmoney has decreased by -46% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Jazz Pharmaceuticals Plc

Vanguard Group Inc
10.10%
BlackRock Inc
9.71%
JPMorgan Chase & Co
5.01%
LSV Asset Management
4.13%
Pacer Advisors, INC.
3.66%
State Street Corp
3.22%

Analyst Recommendation on Jazz Pharmaceuticals Plc

Buy

80%Buy

20%Hold

0%Sell

Based on 25 Wall street analysts offering stock ratings for Jazz Pharmaceuticals Plc(by analysts ranked 0 to 5 stars)

Based on 25 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Jazz Pharmaceuticals Plc Stock (JAZZ)

What analysts predicted

Upside of 48.77%

Target:

$180.95

Current:

$121.63

Insights on Jazz Pharmaceuticals Plc Stock (Ticker Symbol: JAZZ)

Price Movement
In the last 3 months, JAZZ stock has moved up by 11.5%
Increasing Revenue
Revenue is up for the last 3 quarters, 901.98M → 1.05B (in $), with an average increase of 7.4% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -14.61M → 215.05M (in $), with an average increase of 65.1% per quarter
JAZZ vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 58.6% return, outperforming this stock by 59.4%
JAZZ vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 88.8% return, outperforming this stock by 102.3%
Price to Sales
ForJAZZ every $1 of sales, investors are willing to pay $1.9, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $16.6 for every $1 of sales.

JAZZ Jazz Pharmaceuticals Plc Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$1.9B	↑ 16.82%
Net Income	$447.1M	↓ 8.35%
Net Profit Margin	23.64%	↓ 6.5%

	FY19	Y/Y Change
Revenue	$2.2B	↑ 14.32%
Net Income	$523.4M	↑ 17.06%
Net Profit Margin	24.21%	↑ 0.57%

	FY20	Y/Y Change
Revenue	$2.4B	↑ 9.34%
Net Income	$238.6M	↓ 54.41%
Net Profit Margin	10.1%	↓ 14.11%

	FY21	Y/Y Change
Revenue	$3.1B	↑ 30.91%
Net Income	$-329.0M	↓ 237.86%
Net Profit Margin	-10.63%	↓ 20.73%

	FY22	Y/Y Change
Revenue	$3.7B	↑ 18.26%
Net Income	$-214.1M	↓ 34.9%
Net Profit Margin	-5.85%	↑ 4.78%

	FY23	Y/Y Change
Revenue	$3.8B	↑ 4.78%
Net Income	$414.8M	↓ 293.72%
Net Profit Margin	10.82%	↑ 16.67%

	Q2 FY23	Q/Q Change
Revenue	$957.3M	↑ 7.22%
Net Income	$104.4M	↑ 50.44%
Net Profit Margin	10.91%	↑ 3.13%

	Q3 FY23	Q/Q Change
Revenue	$972.1M	↑ 1.55%
Net Income	$146.8M	↑ 40.58%
Net Profit Margin	15.1%	↑ 4.19%

	Q4 FY23	Q/Q Change
Revenue	$1.0B	↑ 4.09%
Net Income	$94.2M	↓ 35.87%
Net Profit Margin	9.3%	↓ 5.8%

	Q1 FY24	Q/Q Change
Revenue	$902.0M	↓ 10.87%
Net Income	$-14.6M	↓ 115.53%
Net Profit Margin	-1.62%	↓ 10.92%

	Q2 FY24	Q/Q Change
Revenue	$1.0B	↑ 13.51%
Net Income	$168.6M	↓ 1253.15%
Net Profit Margin	16.46%	↑ 18.08%

	Q3 FY24	Q/Q Change
Revenue	$1.1B	↑ 3.04%
Net Income	$215.1M	↑ 27.58%
Net Profit Margin	20.38%	↑ 3.92%

	FY18	Y/Y Change
Profit	$1.8B	↑ 17.29%

	FY19	Y/Y Change
Profit	$2.0B	↑ 14.95%

	FY20	Y/Y Change
Profit	$2.2B	↑ 8.89%

	FY21	Y/Y Change
Profit	$2.7B	↑ 19.81%

	FY22	Y/Y Change
Profit	$3.1B	↑ 17.54%

	FY23	Y/Y Change
Profit	$3.4B	↑ 8.97%

	Q2 FY23	Q/Q Change
Profit	$859.8M	↑ 12.51%

	Q3 FY23	Q/Q Change
Profit	$870.0M	↑ 1.19%

	Q4 FY23	Q/Q Change
Profit	$753.1M	↓ 13.43%

	Q1 FY24	Q/Q Change
Profit	$650.8M	↓ 13.59%

	Q2 FY24	Q/Q Change
Profit	$758.7M	↑ 16.59%

	Q3 FY24	Q/Q Change
Profit	$943.4M	↑ 24.34%

	FY18	Y/Y Change
Operating Cash Flow	$798.9M	↑ 15.27%
Investing Cash Flow	$-394.5M	↑ 46.68%
Financing Cash Flow	$-479.1M	↑ 17.11%

	FY19	Y/Y Change
Operating Cash Flow	$776.4M	↓ 2.82%
Investing Cash Flow	$-155.3M	↓ 60.63%
Financing Cash Flow	$-293.7M	↓ 38.69%

	FY20	Y/Y Change
Operating Cash Flow	$899.6M	↑ 15.87%
Investing Cash Flow	$-1.0B	↑ 548.85%
Financing Cash Flow	$528.1M	↓ 279.77%

	FY21	Y/Y Change
Operating Cash Flow	$778.5M	↓ 13.47%
Investing Cash Flow	$-5.2B	↑ 417.25%
Financing Cash Flow	$4.0B	↑ 651.89%

	FY22	Y/Y Change
Operating Cash Flow	$1.3B	↑ 63.39%
Investing Cash Flow	$-446.2M	↓ 91.44%
Financing Cash Flow	$-529.5M	↓ 113.34%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$296.8M	↓ 7.47%
Investing Cash Flow	$-85.7M	↑ 1678.08%
Financing Cash Flow	$-96.7M	↑ 224.52%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$307.2M	↑ 3.51%
Investing Cash Flow	$-174.3M	↑ 103.29%
Financing Cash Flow	$-78.5M	↓ 18.8%

Jazz Pharmaceuticals Plc Technicals Summary

Sell

Neutral

Buy

Jazz Pharmaceuticals Plc is currently in a neutral trading position according to technical analysis indicators.

Jazz Pharmaceuticals Plc (JAZZ) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Jazz Pharmaceuticals Plc	0.12%	8.66%	-2.2%	-13.58%	-14.43%
Biontech Se	-0.32%	51.19%	24.81%	-30.66%	288.02%
Regeneron Pharmaceuticals, Inc.	-6.9%	-37.55%	-28.89%	7.15%	74.63%
Vertex Pharmaceuticals Incorporated	16.87%	0.96%	13.03%	93.36%	95.94%
Alnylam Pharmaceuticals, Inc.	17.76%	5.53%	59.46%	84.7%	118.8%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Jazz Pharmaceuticals Plc	17.62	17.62	0.85	20.2	0.12	0.05	NA	69.01
Biontech Se	160.8	NA	0.04	-3.32	-0.02	-0.01	NA	79.73
Regeneron Pharmaceuticals, Inc.	16.64	16.64	1.08	44.92	0.17	0.07	NA	272.04
Vertex Pharmaceuticals Incorporated	32.84	NA	1.21	0.49	-0.03	0.12	NA	60.65
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.18	-15.01	-0.03	NA	0.25

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Jazz Pharmaceuticals Plc	Buy	$7.5B	-14.43%	17.62	11.6%
Biontech Se	Buy	$29.7B	288.02%	160.8	-15.36%
Regeneron Pharmaceuticals, Inc.	Buy	$74.0B	74.63%	16.64	33.61%
Vertex Pharmaceuticals Incorporated	Buy	$118.9B	95.94%	32.84	-4.51%
Alnylam Pharmaceuticals, Inc.	Buy	$35.0B	118.8%	NA	-15.86%

About Jazz Pharmaceuticals Plc

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Organization	Jazz Pharmaceuticals Plc
Employees	2800
CEO	Mr. Bruce C. Cozadd
Industry	Health Technology

Management People of Jazz Pharmaceuticals Plc

Name	Title
Mr. Bruce C. Cozadd	Co-Founder, Chairman & CEO
Ms. Renee D. Gala	President & COO
Ms. Patricia Carr	Senior VP & Chief Accounting Officer
Ms. Neena M. Patil J.D.	Executive VP & Chief Legal Officer
Dr. Robert Iannone M.D.	Executive VP, Chief Medical Officer and Global Head of Research & Development
Mr. Philip L. Johnson	Executive VP & CFO
Ms. Andrea N. Flynn Ph.D.	VP & Head of Investor Relations
Ms. Heidi Manna	Executive VP & Chief People Officer
Dr. Jed Black M.D.	Senior Vice President of Sleep & CNS Medicine
Ms. Samantha Pearce	Executive VP & Chief Commercial OfficerChief Commercial Officer

Important FAQs about investing in JAZZ Stock from India :

What is Jazz Pharmaceuticals Plc share price today?

Jazz Pharmaceuticals Plc share price today stands at $121.63, Open: $121.07 ; Previous Close: $121.97 ; High: $122.38 ; Low: $120.96 ; 52 Week High: $134.17 ; 52 Week Low: $99.06.

The stock opens at $121.07, after a previous close of $121.97. The stock reached a daily high of $122.38 and a low of $120.96, with a 52-week high of $134.17 and a 52-week low of $99.06.

Can Indians buy Jazz Pharmaceuticals Plc shares?

Yes, Indians can invest in the Jazz Pharmaceuticals Plc (JAZZ) from India.

With INDmoney, you can buy Jazz Pharmaceuticals Plc at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Jazz Pharmaceuticals Plc at zero transaction cost.

How can I buy Jazz Pharmaceuticals Plc shares from India?

It is very easy to buy Jazz Pharmaceuticals Plc from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Jazz Pharmaceuticals Plc (JAZZ) be purchased?

Yes, you can buy fractional shares of Jazz Pharmaceuticals Plc with INDmoney app.

What are the documents required to start investing in Jazz Pharmaceuticals Plc stocks?

To start investing in Jazz Pharmaceuticals Plc, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.